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HIGHLIGHTS
• Many CNS targets are being explored for multi-target drug design
• New databases and cheminformatic methods enable prediction of primary
pharmaceutical target and off-targets of compounds
• QSAR, virtual screening and docking methods increase the potential of rational drug
design
The diverse cerebral mechanisms implicated in Central Nervous System (CNS) diseases
together with the heterogeneous and overlapping nature of phenotypes indicated that
multitarget strategies may be appropriate for the improved treatment of complex brain
diseases. Understanding how the neurotransmitter systems interact is also important in
optimizing therapeutic strategies. Pharmacological intervention on one target will often
influence another one, such as the well-established serotonin-dopamine interaction or
the dopamine-glutamate interaction. It is now accepted that drug action can involve
plural targets and that polypharmacological interaction with multiple targets, to address
disease in more subtle and effective ways, is a key concept for development of novel
drug candidates against complex CNS diseases. A multi-target therapeutic strategy
for Alzheimer‘s disease resulted in the development of very effective Multi-Target
Designed Ligands (MTDL) that act on both the cholinergic and monoaminergic
systems, and also retard the progression of neurodegeneration by inhibiting amyloid
aggregation. Many compounds already in databases have been investigated as ligands
for multiple targets in drug-discovery programs. A probabilistic method, the Parzen-
Rosenblatt Window approach, was used to build a “predictor” model using data
collected from the ChEMBL database. The model can be used to predict both the
primary pharmaceutical target and off-targets of a compound based on its structure.
Several multi-target ligands were selected for further study, as compounds with
possible additional beneficial pharmacological activities. Based on all these findings,
Nikolic et al. Drug Design for CNS Diseases
it is concluded that multipotent ligands targeting AChE/MAO-A/MAO-B and also
D1-R/D2-R/5-HT2A-R/H3-R are promising novel drug candidates with improved efficacy
and beneficial neuroleptic and procognitive activities in treatment of Alzheimer’s and
related neurodegenerative diseases. Structural information for drug targets permits
docking and virtual screening and exploration of the molecular determinants of binding,
hence facilitating the design of multi-targeted drugs. The crystal structures and models of
enzymes of the monoaminergic and cholinergic systems have been used to investigate
the structural origins of target selectivity and to identify molecular determinants, in order
to design MTDLs.
Keywords: multi-target drugs, CNS disease, QSAR, rational drug design, cheminformatic, virtual screening, virtual
docking
POLYPHARMACOLOGY OF COMPOUNDS
AGAINST CNS DISEASES
Traditional drug discovery methods have mainly been based
on development of selective agents for a specific target able
to modulate its activity and the pathophysiology of the
disease. This approach in now generally recognized as too
simplistic for designing effective drugs to address complex
multifactorial diseases, characterized by diverse physiological
dysfunctions caused by dysregulation of complex networks
of proteins (Anighoro et al., 2014). Modern drug design of
multitarget ligands able to specifically modulate a network
of interacting targets and show unique polypharmacological
profiles is becoming increasingly important in drug discovery
for multifactorial pathologies such as complex central nervous
system (CNS) diseases (Hopkins, 2008; Mestres and Gregori-
PuigjaneÌA˛, 2009; Boran and Iyengar, 2010; Peters, 2013;
Anighoro et al., 2014).
Themost significant advantages of the use ofmultitarget drugs
over other therapeutic strategies, such as polypharmaceutical
or single-targeted therapy, are: improved efficacy as result of
synergistic or additive effects caused by simultaneous and specific
interactions with chosen palette of biological targets; better
distribution in target tissue for simultaneous action on multiple
targets; accelerated therapeutic efficacy in terms of initial onset
and achievement of full effect; treatment of broader therapeutic
range of symptoms; predictable pharmacokinetic profile and
mitigated drug-drug interactions; lower incidence of molecule-
based side effects; increased therapeutic interval of doses as
result of lower risk of acute and delayed toxicity; better quality
of treatment; improved patient compliance and tolerance; and
lower incidence of target-based resistance as result of modulation
of multiple targets (Millan, 2006, 2014; Anighoro et al., 2014).
The main challenge in drug discovery of MTDLs is to develop
an efficient methodology for the design of novel multipotent
Abbreviations: MTDL, multi-target designed ligands; QSAR, quantitative
structure-activity relationship; AD, Alzheimer’s disease; PD, Parkinson’s disease;
AChE, acetylcholinesterase; BuChE, butyrylcholinesterase; MAO, monoamine
oxidase; Aβ, amyloid beta; 5-HT, serotonin receptor; D-R, dopamine receptor;
H-R, histamine receptor, GPCRs, G protein–coupled receptors; HMT, histamine
N-methyltransferase; SERT, serotonin transporter; AMPK, 5′ ’-adenosine
monophosphate-activated protein kinase.
drugs able to interact only with one additional target and without
significant affinities for other related targets.
The polypharmacological design of CNS drugs is challenging
because of the complex pathophysiological mechanisms of brain
diseases, interactions of neurotransmitter systems and observed
ligand cross-reactivities (Roth et al., 2004). Since multipotent
ligands could also interact with off-targets and cause target-
based adverse effects, a major objective in polypharmacology
is to rationally design multi-target drugs able to specifically
modulate only a group of desired targets while minimizing
interactions with off-targets and avoiding interactions with
anti-targets (Anighoro et al., 2014; Millan, 2014). Multi-Target
Designed Ligands (MTDL) contain the primary pharmacophore
elements for each target which could be separated by a linker
(conjugateMTDLs), could touch at one point (fused), or could be
combined by using commonalities in the structures of underlying
pharmacophores (merged) (Besnard et al., 2012; Millan, 2014).
Smaller and relatively rigid structures of highly merged
MTDLs result in better physicochemical, pharmacokinetic and
pharmacological profiles (Besnard et al., 2012; Millan, 2014).
For the rationally designed MTDLs, activities against the targets
and pharmacokinetic profiles are predicted. Based on the results
obtained, the most promising MTDLs are selected for further
modifications and studies (Hajjo et al., 2010; Besnard et al., 2012;
Hajjo et al., 2012; Zhang et al., 2013; Nikolic et al., 2015a).
Several previous studies confirmed that multifactorial
pathologies, such as cerebral mechanisms implicated in
neurological and psychiatric diseases (Threlfell et al., 2004; Dai
et al., 2007; Garduno-Torres et al., 2007; Humbert-Claude et al.,
2007; Gemkow et al., 2009) and neurodegenerative disorders
(Goedert and Spillantini, 2006), are often polygenic and involve
the dysregulation of very complex networks of proteins. The
diverse cerebral mechanisms implicated in CNS diseases together
with the heterogeneous and overlapping nature of phenotypes
indicated that multitarget strategies may be appropriate for
improved treatment of complex brain diseases. Both the activity
and the side effects of CNS drugs are characterized by a complex
pattern of biological activities on multiple targets and a complex
mechanism of action (Roth et al., 2004; Lipina et al., 2012, 2013).
Understanding how the neurotransmitter systems interact is also
important in optimizing therapeutic strategies. Pharmacological
intervention on the dopamine system will often influence the
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serotonin or glutamate neurotransmitter systems. Interactions of
the neurotransmitter systems, such as the dopamine-glutamate
interaction (Carlsson and Carlsson, 1990; Millan, 2005) and the
serotonin-dopamine interaction (Di Giovanni et al., 2008; Di
Matteo et al., 2008), are also very important factors in design of
multitargeted ligands with specific cross-reactivity and optimized
neuropharmacological effects (Youdim and Buccafusco, 2005).
Therefore, a more efficient polypharmacological strategy for
treatment of complex CNS diseases is based on drug interactions
with multiple targets, to address disease in more subtle and
effective ways while avoiding side effects arising from interaction
with defined antitargets and off-targets (Lu et al., 2012; Anighoro
et al., 2014). Thus, polypharmacology is now recognized as a
key pharmacological concept for development of novel drug
candidates against complex CNS diseases.
As a result of the multitarget approach (Morphy and
Rankovic, 2005; León et al., 2013; Anighoro et al., 2014;
Millan, 2014) many CNS drugs with improved efficacy
compared to their lead compounds have been developed and
examined. Monoamine reuptake inhibitors with serotonin 5-
HT2C antagonistic properties were developed as novel class of
antidepressants (Millan, 2006; Meltzer et al., 2012; Quesseveur
et al., 2012). Dopamine receptors are G protein–coupled
receptors (GPCRs), distinct in pharmacology, amino acid
sequence, distribution, and physiological function. Based on their
effector-coupling profiles dopamine receptors are organized into
two families, the D1-like (D1, D5) and D2-like (D2, D3, D4)
receptors (Brunton et al., 2011).
The physiological processes under dopaminergic control
include reward, emotion, cognition, memory, and motor
activity. Therefore, dysregulation of the dopaminergic system
is critical in a number of disease states, including Parkinson’s
disease, Tourette’s syndrome, bipolar depression, schizophrenia,
attention deficit hyperactivity disorder, and addiction/substance
abuse (Brunton et al., 2011). Dopamine receptor antagonists are
a mainstay in the pharmacotherapy of schizophrenia.
Since the pathophysiology of schizophrenia and related
diseases involves deregulation of the dopamine, serotonin and
glutamate neurotransmitter systems (Witkin and Nelson, 2004;
Esbenshade et al., 2008; Brunton et al., 2011), therapeutic effects
of typical and atypical neuroleptics are mostly mediated by
inhibition of dopamine D1/D2-like receptors and other related
aminergic receptors (Table 1). Blockade of dopamine D2 and
serotonin 5-HT2A receptors is the main mechanism of action
of atypical antipsychotics (Remington, 2003). Furthermore,
interaction with various dopamine (D1, D3, D4), serotonin
(5-HT1A, 5-HT1D, 5-HT2A, 5-HT2C, 5-HT6, and 5-HT7), and
histamine H3 receptors may produce additional antipsychotic
or procognitive effects (Reynolds, 2004; Esbenshade et al., 2008;
Coburg et al., 2009) by indirectly modulating the mesolimbic
dopaminergic neurons (Amato, 2015).
A significant improvement in schizophrenia therapy came
in the early 2000s with the use of aripiprazole acting as a
dopamine D2-like partial agonist with partial agonistic properties
on serotonergic 5-HT1A and 5-HT2A receptors (Buckley, 2003;
Kiss et al., 2010; Johnson et al., 2011). Dopamine D2/D3
antagonists, with 5-HT2A antagonistic and 5-HT1A partial
agonistic activities, were proposed as drug candidates for
schizophrenia therapy (Roth et al., 2004; Lipina et al., 2012, 2013).
The efficient polypharmacological profile of aripiprazole and
related antipsychotics resulted in the development of cariprazine
and pardoprunox as drug candidates, which are currently in
clinical trials (Ye et al., 2014).
Despite selective D1 antagonism not being accepted on its
own as an effective antipsychotic principle (Table 1; Tauscher
et al., 2004; Sedvall and Karlsson, 2006), moderate antagonistic
activity at D1-receptors has been confirmed to be responsible
for atypical neuroleptic clozapine effectiveness against treatment-
resistant schizophrenia (Tauscher et al., 2004). Based on the
polypharmacological profiles of recently approved antipsychotic
drugs, it could be concluded that optimal and balanced
modulation of D1/D2-like receptors - as well as interaction
with serotonin and histamine H3 receptors - should provide
the most favorable neuroleptic effect. The successfully developed
effective MTDLs with optimal polypharmacological profile
for CNS diseases (Table 1) are experimental proof of the
polypharmacological concept. Polypharmacological approaches
are therefore likely to be extensively applied for rational design
of ligands with optimal multitarget profile and for discovery of
multipotent drug candidates with improved efficacy and safety in
therapy of complex brain diseases.
Novel procognitive agents were developed as histamine H3R
antagonists/inverse agonists with inhibition of acetylcholine
esterase (AChE), monoamine oxidase (MAO), histamine N-
methyltransferase (HMT), or serotonin transporter (SERT)
(Ligneau et al., 1998; Apelt et al., 2002, 2005; Grassmann et al.,
2003, 2004; Petroianu et al., 2006; Decker, 2007; Esbenshade et al.,
2008; Sander et al., 2008; Coburg et al., 2009; Bajda et al., 2011;
Nikolic et al., 2015a). Rasagiline and ladostigil, drugs currently
used as selective MAO-B inhibitors in therapy of PD, contain
the propargylamine scaffold and therefore exert significant
neuroprotective activity. Thus, phase II clinical trials of rasagiline
(www.clinicaltrials.gov/ct2/show/NCT00104273) and ladostidil
(www. clinicaltrials.gov/ct2/show/NCT01354691) in therapy of
AD were proposed, and subsequently successfully completed.
A multi-target therapeutic strategy for Alzheimer‘s disease
resulted in the development of very effective MTDLs that act
on both the cholinergic and monoaminergic systems, and also
retard the neurodegenerative progress by inhibiting amyloid
aggregation. Multi-target inhibitors of acetylcholine esterase
and MAO (AChE/BuChE/MAO-A/MAO-B) were effective drug
candidates for therapy of neurodegenerative Alzheimer’s (AD)
and Parkinson’s diseases (PD) (Pérez et al., 1999; Marco-
Contelles et al., 2006, 2009; Bolea et al., 2011; León et al., 2013;
Bautista-Aguilera et al., 2014a,c; Nikolic et al., 2015b).
Besides the difficulties of effective modulation of the CNS
targets, the need to design drugs that are able to reach the targets
in the brain increases the complexity of CNS drug discovery.
This is mainly due to the blood-brain barrier (BBB) protection
system between the blood capillaries of the brain and brain
tissue (Pardridge, 2005). The BBB enables selective access of
required nutrients and hormones, while removing waste and
preventing or reducing penetration of xenobiotics (Pardridge,
2005). Therefore, a major challenge in CNS drug discovery is
to build and apply relationships between chemical structure
and brain exposure (Rankovic and Bingham, 2013; Rankovic,
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TABLE 1 | Polypharmacological profiles of drugs and drug candidates affecting the dopaminergic system.
Compound Targets
Aripiprazole (Johnson et al., 2011)
D2, D3, 5-HT2B, D4, 5-HT2A, 5-HT1A, 5-HT7, α1A, H1 receptors (Buckley, 2003; Shapiro et al., 2003)
Amitriptyline (Coburg et al., 2009)
D1, D5, D2, D3, H1 receptors (Ligneau et al., 2000)
Chlorpromazine (Bourne, 2001)
D1, D5, D2, D3, D4, 5-HT2a receptors (Rajagopalan et al., 2014)
Clozapine (Coburg et al., 2009)
D1, D5, D2, D3, D4, 5-HT2A, H1 receptors (Ligneau et al., 2000; Bourne, 2001; Rajagopalan et al., 2014)
Chlorprothixene (Coburg et al., 2009)
D1, D5, D2, D3, D4, H1 receptors (Ligneau et al., 2000)
Fluphenazine (Coburg et al., 2009)
D1, D5, D2, D3, D4, H1 receptors (Ligneau et al., 2000)
(Continued)
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TABLE 1 | Continued
Compound Targets
Haloperidol (Bourne, 2001)
D1, D5, D2, D3, D4, 5-HT2A receptors (Hamacher et al., 2006)
SCH 23390 (Bourne, 2001)
D1, D5, D2, D3, D4, 5-HT2A, 5-HT, α2Areceptors (Wu et al., 2005)
SCH 39166 (Wu et al., 2005)
D1, D5, D2, 5-HT, α2A receptors
13 (Coburg et al., 2009)
D1, D5, D2, D3, D4, H1, H3 receptors (Ligneau et al., 2000; Bourne, 2001; Hamacher et al., 2006;
Rajagopalan et al., 2014)
2015a). Total brain concentration (Cb) is now recognized as
being only a portion of the non-specific binding to brain tissue,
while the unbound brain concentration (Cu,b) is defined as the
drug concentration at the target sites and is a measure of in vivo
drug efficacy. Finally, receptor occupancy (RO) is direct measure
of target engagement (Rankovic, 2015b). Lipophilicity of CNS
drugs is generally considered the most critical physicochemical
parameter for improved penetration and potency. Higher
lipophilicity causes low solubility, high plasma protein binding,
and increased metabolic and toxicity risks in CNS drugs
(Leeson and Springthorpe, 2007). Furthermore, hydrogen bond
molecular parameters are the dominant descriptors for unbound
drug brain concentrations (Leeson and Davis, 2004). Reducing
the HBD (Hydrogen Bond Donor) count of a molecule is one of
the most successful strategies used in the optimization of brain
exposure (Weiss et al., 2012). In CNS drug discovery, aqueous
solubility is also considered in combination with the previously
described parameters. Most of the CNS drugs with low safety
risk are very soluble compounds, displaying aqueous solubility of
more than 100µM(Alelyunas et al., 2010). Generally, fine-tuning
physicochemical properties for optimal brain exposure is now
an essential method in CNS drug discovery (Table 2). Further
studies of CNS property space and development of predictive
models for brain exposure should result in the formation of a
general methodology with a wide applicability domain in CNS
drug design.
3D-QSAR STUDY OF MULTITARGET
COMPOUNDS FOR CNS DISEASES
QSAR (Quantitative Structure-Activity Relationship) modeling
has progressed from analysis of small series of congeners using
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TABLE 2 | Developing CNS property space for optimal brain exposure (Rankovic and Bingham, 2013; Rankovic, 2015b).
CNS property space
TPSA < 60 Å2, pKa < 8 and HBD count < 2 are minimizing P-gp recognition (Hitchcock, 2012; Desai et al., 2013)
TPSA (25–60 Å2); at least one N atom; linear chains outside of rings (2–4); HBD (0–3); volume (740–970 Å3); SAS (460–580 Å2)→ ↑BBB penetration (Ghose et al., 2012)
Optimal cLogP <3 (Gleeson, 2008)
cLogP < 4 and TPSA 40–80 Å2 → ↑Cu,b (Raub et al., 2006)
PSA < 90 Å2; HBD < 3; cLogP 2–5; cLogD (pH 7.4) 2–5; and MW < 500→ ↑BBB penetration (Hitchcock and Pennington, 2006)
MW < 450; cLogP < 5; HBD < 3; HBA < 7; RB < 8; H-bonds < 8; pKa 7.5–10.5; PSA < 60–70 Å2.→ ↑BBB penetration (Pajouhesh and Lenz, 2005)
TPSA, topological polar surface area; Å2, square angstrom; Å3, qubic angstrom; HBD, hydrogen-bond donors; P-gp, P-glycoprotein; BBB, blood-brain bariere; HBA, hydrogen-bond
acceptors; MW, molecular weight; PSA, polar surface area; cLogP, partition coefficient; cLogD, distribution coefficient; RB, rotatable bonds; Cu,b, unbound drug concentrations in brain;
↓, decreased; ↑, increased.
basic regressions to applications on very large and diverse
data sets using a variety of statistical and machine learning
methods. Today’s QSAR practice widely uses ligand based
theoretical approaches for modeling the physical, biological and
pharmacological properties of compounds, and forms a crucial
initial step in drug discovery. Together with structure-based
methods, statistically based QSAR techniques are essential tools
in lead optimization within several leading drug discovery groups
(Cramer, 2012; Cherkasov et al., 2014).
Modern QSAR methodologies started with a 1962 publication
by the Hansch group (Hansch et al., 1962), and further developed
with the exploration of series of congeners (Craig, 1971; Topliss,
1972; Hansch et al., 1973). Steric effects of substituents were
successfully described by five shape descriptors for substituents
(Verloop et al., 1976). Electrostatic interaction energies in a series
of superimposed 3D-conformations of analogs were effectively
included in CoMFA (Comparative Molecular Field Analysis) and
other 3D-QSAR methods (Cramer et al., 1988). In CoMFA,
steric and electrostatic molecular fields of ligands are calculated
and correlated with bioactivities by use of PLS (Partial Least
Squares) (Wold et al., 1984). Based on the CoMFA approach, the
CoMSIA method (Molecular Similarity Indices in a Comparative
Analysis) was developed (Klebe et al., 1994), encompassing the
steric, electrostatic, hydrogen bonding and hydrophobic effects
of ligands. The main limitation of CoMFA/CoMSIA and other
3D-QSAR methods relates to their being applicable only to static
structures of chemical analogs, while neglecting the dynamical
nature of the ligands (Acharya et al., 2011).
Molecular field generating software, such as GRID (Goodford,
1985) and PHASE (Dixon et al., 2006), historically applied
pharmacophoric constraints to facilitate 3D-QSAR modeling,
considering multiple conformations. The new generation of
3D-descriptors, such as GRIND/GRIND-2/GRID-PP (Grid-
Independent Descriptor), are alignment free descriptors derived
from the Molecular Interaction Fields (MIF) of the series and
designed to retain the chemical characteristics of the ligands
examined. The GRIND descriptors so obtained are provided by
programs from Molecular Discovery (Pastor et al., 2000; Durán
et al., 2009) and used for advanced multivariate analyses and
3D-QSAR modeling.
Some novel 3D-QSAR approaches based on ligand-based
3D-QSAR models and complementary drug target fields are
included in the AFMoC (Gohlke and Klebe, 2002) and QMOD
(Varela et al., 2012) programs. The QSAR study of multitarget
compounds involves QSAR modeling for each target activity
individually, study of all developed QSAR models as part in a
network of interrelated models, and design of novel multipotent
compounds (Cherkasov et al., 2014). Combinations of the
QSAR approach and related theoretical methods, such as virtual
screening and docking, are very useful in the study and design
of multitarget ligands with unique polypharmacological profiles
(Figure 1; Ning et al., 2009; Zheng et al., 2010; Besnard et al.,
2012; Kupershmidt et al., 2012; Bolea et al., 2013; Bautista-
Aguilera et al., 2014c). Based on the developed QSAR models,
analogs of a multitarget lead are designed with enhanced activity
on the targets and optimal polypharmacological and safety
profiles as drug candidates for further study. Recently developed
QSAR approaches were the only in silico methodologyies able
to distinguish between antagonists and agonists of olfactory
receptors (ORs), a superfamily of G-protein coupled receptors
(Don and Riniker, 2014).
Several successful cases of reported 3D-QSAR studies
used in CNS drugs discovery have been listed in Table 3. In
this chapter we provide an overview of some of them. For
example, polypharmacological profiles of in silico generated
analogs of donepezil, an approved acetylcholinesterase inhibitor
drug, were evaluated by a QSAR study. More than 75% of
the ligand-target predictions were confirmed by in vitro
testing (Besnard et al., 2012). Pathophysiology of Alzheimer’s
disease (AD) includes extracellular deposition of amyloid β
peptide (Aβ)-containing plaques, progressive loss of cholinergic
neurons, metal dyshomeostasis, mitochondrial dysfunction,
neuroinflammation, oxidative stress and increased MAO
enzyme activity. Furthermore, levels of neurotransmitters such
as dopamine, noradrenaline, and serotonin are significantly
decreased in AD patients (Reinikainen et al., 1990). MAO-A/B
inhibitors could increase the levels of dopamine, noradrenaline,
and serotonin in the CNS. Therefore, MAO-A/B inhibitors have
also been proposed as potential drugs for AD (Youdim et al.,
2006).
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FIGURE 1 | Computer-aided rational design of multipotent ligands with controlled polypharmacology.
TABLE 3 | Reported 3D-QSAR studies used in CNS drug discovery.
Drug target CNS disease 3D-QSAR method Software package References
MAO-A, MAO-B,
AChE, BuChE
AD GRID based 3D-QSAR modeling
(Goodford, 1985; Pastor et al., 2000;
Durán et al., 2009)
Pentacle www.moldiscovery.com Bautista-Aguilera
et al., 2014a,b
AChE AD Molecular field based 3D-QSAR
modeling (Dixon et al., 2006)
PHASE www.schrodinger.com Lakshmi et al.,
2013
AChE, BuChE AD CoMFA based 3D-QSAR modeling
Wold et al. (1984)
Tripos Sybyl www.tripos.com Li et al., 2013
AChE AD 3D multi-target QSAR (Prado-Prado
et al., 2012)
DRAGON http://www.talete.mi.it/ MARCH-INSIDE
(MARkovian CHemicals IN SIlico DEsign)
González-Díaz
et al., 2012
H3-R, HMT, AChE,
BuChE
AD, PD,
depression,
schizophrenia
Molecular field and GRID based
3D-QSAR modeling (Goodford, 1985;
Pastor et al., 2000; Dixon et al., 2006;
Durán et al., 2009)
PHASE www.schrodinger.com Pentacle
www.moldiscovery.com
Nikolic et al.,
2015a
Multimodal brain permeable drugs affecting a few brain
targets involved in the disease pathology, such as MAO
and ChE enzymes, iron accumulation and amyloid-β
generation/aggregation, were extensively examined as an
essential therapeutic approach in AD treatment (Zheng et al.,
2010; Bautista-Aguilera et al., 2014b). For instance, hybrid
compound M30D contains the important pharmacophores
from three drugs: tacrine, rivastigmine (ChEIs) and
rasagiline/ladostigil (MAO-B inhibitor) (Zheng et al., 2010),
while ASS234 and MBA236 contain the pharmacophores
of the drugs donepezil (ChEIs) and clorgiline (MAO-A
inhibitor) (Bolea et al., 2011). Pharmacophore and 3D-QSAR
studies of donepezil and clorgiline derivatives inhibiting both
AChE/BuChE and MAO-A/B were successfully applied for lead
optimization work and for design of ASS234, MBA236
and related ligands with optimal polypharmacological
and pharmacokinetic profiles (Bautista-Aguilera et al.,
2014a,b,c). The propargylamine moiety in the MAO-
inhibiting pharmacophore of rasagiline, ladostigil or clorgiline
is responsible for their neuroprotective-neurorestorative effects.
Therefore, the propargylamine moiety was used as the main
chemical scaffold responsible for MAO inhibition in the
designed M30D, ASS234, and MBA236 hybrids (Figure 2).
Hybrid compound ASS234 acted as an 11-fold less potent
MAO-A inhibitor and 54-fold more potent MAO-B inhibitor
than the reference compound clorgiline, while MBA236 was
nine times more potent as an MAO-A inhibitor and 6-fold more
potent for MAO-B than reference compoundASS234. Inhibition
of the ChEs by the hybrid MBA236 is in the micromolar range,
slightly better than compound ASS234 for AChEs while slightly
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poorer for BuChE (Table 4; Bautista-Aguilera et al., 2014b). The
Multi-Target Designed Ligand M30D was found to be a highly
potent inhibitor of MAO-A with moderate MAO-B inhibiting
activity. Also, M30D was a more potent AChE inhibitor than
rivastigmine, while rivastigmine was a much stronger BuChE
inhibitor than M30D (Table 4; Zheng et al., 2010). Further to
their MAO/ChE inhibitory properties, ASS234 and M30D exert
beneficial pharmacological effects in therapy of AD by inhibiting
Aβ plaque formation and aggregation and, by blocking AChE-
mediated Aβ1-40/Aβ1-42 aggregation (Kupershmidt et al., 2012;
Bolea et al., 2013).
CHEMINFORMATICS METHODS FOR
ON-TARGET AND OFF-TARGET
BIOACTIVITY PREDICTION
The prediction of interactions between druglike organic
molecules and proteins is a ubiquitous goal at the interface
of biology and chemistry. The problem is approached from
various different directions and with diverse purposes in mind.
Much of this section will discuss the use of cheminformatics
TABLE 4 | IC50 values for the inhibitory effects of test compounds on the
enzymatic activity of MAO-A, MAO-B, AChE, and BuChE.
Compound MAO-A MAO-B AChE BuChE
MBA236a 6.3 ± 0.4 nM 183.6 ± 7.4 nM 2.8 ± 0.1 µM 4.9 ± 0.2 µM
ASS234a 58.2 ± 1.2 nM 1.2 ± 0.1 µM 3.4 ± 0.2 µM 3.3 ± 0.2 µM
Clorgilinea 4.7 ± 0.2 nM 65.8 ± 1.6 µM ** **
M30Db 7.7 ± 0.7 nM 7.9 ± 1.3 µM 0.5 ± 0.1 µM 44.9 ± 6.1 µM
aBautista-Aguilera et al. (2014b).
bZheng et al. (2010).
**Inactive at 100 µM (highest concentration tested).
methods to identify likely interactions between ligands, as the
organic molecules are collectively called, and proteins. Such
predictions may have many uses in terms of understanding the
likely bioactivities of molecules and both cellular and molecular
functions of proteins.
The prediction of pharmaceutically relevant molecular
properties has been the default problem addressed by
cheminformatics throughout its history. The most obvious
application, and a useful source of financial support, for
cheminformatics research has been drug discovery. The label
“drug discovery,” however, obscures the complexity of a variety
of distinct questions. One objective, early in the drug discovery
pipeline, is the identification of lead compounds, molecules
possessing modest pharmacological activity that are starting
points for chemical modifications enhancing their potency,
selectivity and bioavailability. Subsequently, lead optimization
will require Quantitative Structure-Activity Relationship (QSAR)
studies to understand which modifications will best enhance
affinity while, for instance, maximizing solubility and avoiding
regions of chemical space likely to lead to toxicity.
Protein target predictions (Bender et al., 2007; Lounkine
et al., 2012) allow us to link molecular interactions to biological
effects, and hence to identify and rationalize the bioactivities
of compounds. Since many molecules interact promiscuously
with several targets as well as different ligands interacting
with the same target (Figure 3), we must predict off-target
as well as on-target interactions. Protein-ligand interactions,
other than those with the expected pharmacological protein
target, can help to identify opportunities for drug repurposing
(Kinnings et al., 2011; Napolitano et al., 2013), where a
drug developed for one disease is able to treat a different
condition. Such compounds have the advantage of already
having been optimized for bioavailability and non-toxicity. More
adventurously, polypharmacology (Chen et al., 2009) is possible,
where deliberate use ismade of the drug’s ability to hit two targets,
FIGURE 2 | Structures and pharmacophores of effective Multi-Target Designed Ligands against AD. Blue coloring represents the MAO inhibitor
pharmacophore and red represents the ChE inhibitor pharmacophore.
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FIGURE 3 | Illustrations of the cases of a promiscuous ligand and a promiscuous target (left and right, respectively).
permitting more subtle modulation of its effect on a disease.
Just as importantly, off-target prediction can identify likely side-
effects (Lounkine et al., 2012) and adverse drug reactions (Bender
et al., 2007).
Similarity-Based Methods
One of the core methodologies of cheminformatics is the use of
molecular similarity to predict bioactivity. In the simplest single-
target cases, an in silico library of chemical structures is compared
with those chemical structures known to possess bioactivity
against that protein. Molecules are usually represented by one
of the many sets of fingerprints or descriptors (Steinbeck et al.,
2003; Bender et al., 2004) that distil various chemical, topological
and physicochemical properties of a molecular structure into a
string of tens to hundreds of bits. This exercise is predicated
on the Similar Property Principle, that structures close together
in the vector space defined by the descriptors should possess
similar chemical or biochemical properties. Thus, proximity in
an arbitrary chemical space is used as a proxy for likely similarity
of properties. This is an extremely common approach for lead
identification.
Adaptation of Similarity Approaches to
Off-Target Prediction
We have created our own similarity-based procedure that has
two significant modifications and is particularly suitable for
use on multi-target problems with some missing data. This
workflow has been applied in our work to two specific problems:
the identification of performance-enhancing molecules that
should be prohibited in sports (Mavridis and Mitchell,
2013), and predicting multi-target bioactivities of potential
polypharmacological compounds for treatment of neurological
diseases (Nikolic et al., 2015b).
The first methodological modification is that we do not base
our search on single known actives, but rather on families
of compounds. We define our families on the twin criteria
of bioactivity against a particular protein family and cluster
membership (Mavridis et al., 2013) of structurally similar ligands.
For each target, we obtain one or often more refined families, as
we call them, of compounds sharing both a structural scaffold and
a target-specific bioactivity in common.
Our second modification was to devise a quantitative method
of estimating the probability that a given query molecule is
associated with a particular bioactivity-scaffold combination
defining one specific refined family. This allows us to make
comparable predictions across both on-target and off-target
activities based on the current 1,715,667 compounds and 10,774
targets in the ChEMBL database (Gaulton et al., 2012). Doing
this requires us to create a common scale for the different
affinity measures reported in the literature, (IC50, Ki, Kd, EC50,
ED50, potency, activity, inhibition) relevant to bioactivity. We
applied a number of rules in order to generate sets of molecules
experimentally reported to be bioactive, given affinities defined
using the eight different measures, separating these from sets
of inactive molecules. Those empirical rules were derived by
considering the distributions of the different affinity measures
amongst reported active and inactive compounds. Subsequently,
we use the Parzen-Rosenblatt (PR) (Rosenblatt, 1956; Parzen,
1962) kernel density estimation method to transform Tanimoto
similarities into probabilities of family membership.
Our study of molecules related to doping in sport (Steinbeck
et al., 2003) used protein target prediction to predict athletic
performance-enhancing properties. In it, we demonstrated that
the freely available ChEMBL database can be clustered into
bioactivity-based refined families of ligands, using our clustering
algorithm PFClust (Mavridis and Mitchell, 2013). These refined
families consist of distinct sets of compounds, each set with its
own molecular scaffold. For example, we separated the ligands
for the beta-2 adrenergic receptor, a target hit by many beta
blockers, into two distinct families with each ligand generating
a high probability of belonging to just one or other of the two
groups and a lower score for the alternative refined family, as
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shown in Figure 4. The use of such structurally distinct refined
families significantly improved our method’s performance in
cross-validation, to the extent of giving encouraging concordance
with experiment. Overall, two thirds of our test cases in cross-
validation had the correct refined family as the number one
prediction, and seven eighths had this “correct” family among
the top four hits. We sometimes found many different scaffolds
for one target; for the androgen receptor ligands PFClust
generated 126 different refined families. Even where we have no
experimental data, we can still undertake predictions of the likely
bioactivity. We identified the protein targets corresponding to
seven of the World Anti-Doping Agency’s defined prohibited
classes of compounds; we found a mixture of expected and
surprising protein targets. Many of the apparently unexpected
targets, however, turned out to have published biochemically or
clinically validated links to the relevant bioactivities.
We recently studied (Nikolic et al., 2015b)multi-target ligands
intended to interact with MAO A and B; acetylcholinesterase
(AChE) and butyrylcholinesterase (BuChE); or with histamine
N-methyltransferase (HMT) and histamine H3-receptor (H3R).
These enzymes are all potential drug targets for neurological
conditions, including depression, Alzheimer’s disease, obsessive
disorders, and Parkinson’s disease. Three groups of dual
or multi-target compounds facilitated the generation of 3D-
QSAR models for activity against the aforementioned protein
targets. The first set of ligands consisted of novel carbonitrile–
aminoheterocyclic compounds, designed to inhibit both MAO
A and B. Amongst these, dicarbonitrile aminofuran derivatives
were generally more selective MAO A inhibitors. The second
group included acetylene-, indol-, piperidine- and pyridine-
derivatives, which exhibited polypharmacology against MAO
A/B, AChE, and BuChE. These agents are putative multitarget
compounds against Alzheimer’s disease. The third set of
ligands contained multipotent histamine H3R antagonists that
can concurrently inhibit HMT, and are therefore two-target
procognitive compounds with potential therapeutic application
against several psychiatric and neurodegenerative diseases.
We used the Parzen–Rosenblatt kernel approach to build
probabilistic models for both primary targets and off-targets,
using data collected from the ChEMBL (Nikolic et al., 2015b) and
DrugBank (Knox et al., 2011) databases. The cheminformatics-
based target identifications agreed with four 3D-QSAR models
for the various receptors, and with in vitro assays for serotonin 5-
HT1A and 5HT2A receptor binding of the most promising ligand.
As a result of this work, this and several othermulti-target ligands
were chosen for further investigation of their possible additional
beneficial pharmacological activities.
Ain et al. (2014) used both protein and ligand descriptors to
model the multi-target inhibitory profiles of serine proteinase
inhibitors. They built separate sets of Random Forest (Breiman,
2001) models, some using only ligand descriptors, which they
called “QSAR models,” and others built using also protein
descriptors, namely “proteochemometric (PCM)models”. Across
12,625 inhibitors and 67 targets, they found that the models
including protein descriptors performed substantially better than
ligand-only ones, in terms of both R2 (0.64 v 0.35) and root mean
squared error (0.66 v 1.05 log units). They found that both the
binding site amino acids and the protein sequence corresponded
to important protein descriptors in their models.
Relationship to Protein Structure
Prediction
Ain et al.’s finding that the best models require protein
information (Ain et al., 2014) is particularly interesting. We
recently asked why sequence-based protein function prediction
methods work so effectively. For example, De Ferrari et al.
obtained 98% prediction accuracy for enzyme function, based
on transferring annotations from a query sequence’s nearest
neighbor of known function (De Ferrari et al., 2012). We
have recently demonstrated that the majority of the predictive
power of such sequence signature-based methods comes from
the wealth of evolutionary information contained in the whole
sequence, and only a small part of the predictive ability emanates
from the many fewer functionally essential conserved residues
(Beattie et al., 2015). In the context of polypharmacology
and off-target interactions, structure-based methods of protein
function prediction (Laskowski et al., 2005; Pal and Eisenberg,
2005; Cuff et al., 2011) are also highly relevant. Unexpected
ligand-target interactions can be discovered by cross-docking
the library of compounds into the active sites of the known
structures of the various proteins (Favia et al., 2008; Patel et al.,
2015). This methodology, however, requires an experimental
protein structure, or at least a high-quality structural model, for
the target, and is computationally much more expensive than
cheminformatics.
As well as predicting interactions with a protein’s major
functional site, which we term orthosteric, it is also possible to
predict allosteric ligand function. For example, van Westen et al.
predicted allosteric behavior of compounds based on structural
and chemical descriptors and data from ChEMBL (van Westen
et al., 2014). As well as such predictions of allosteric molecules,
it is also important to be able to predict which proteins will be
amendable to allosteric proteins and which residues or clefts may
be involved. We have recently used a Random Forest model to
predict the presence of allosteric binding sites on proteins, based
on structure, solvent accessibility and predicted binding affinity
(Chen et al., 2016). Other predictions of allostery are derived
from reduced models of protein dynamics, for instance using
normal mode analysis (Panjkovich and Daura, 2012) or modeling
energy flow within the protein structure (Erman, 2011).
VIRTUAL SCREENING OF MULTITARGET
COMPOUNDS FOR CNS DISEASES
Virtual Screening (VS) is widely used in drug discovery to reduce
the enormous compound collections to a more manageable
number for further synthesis and biological in vitro testing
(Alvarez, 2004). The application of computational technologies
has allowed medicinal chemists to develop new drugs in a
time and cost-effective manner. Two generally accepted VS
methods used in Computer Aided Drug Design (CADD)
are classified as Ligand-Based Virtual Screening (LB-VS) and
Structure-Based Virtual Screening (SB-VS) (Figure 5; Wilson
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FIGURE 4 | Example case for the World Anti-Doping Agency data: the assignment of prohibited beta blockers to the Beta-2 adrenergic receptor family
of ChEMBL (210).
FIGURE 5 | Schematic representation of the virtual screening strategy.
and Lill, 2011). Ligand-based VS approaches are often applied
when no structural information about the target protein is
available and analyze the physicochemical similarity between
large compound databases and known active molecules. On
the other hand, the structure-based VS approach applies
different modeling techniques, often including docking, to mimic
the binding interaction of ligands to a biomolecular target.
In both VS approaches, structures from virtual libraries or
commercial databases are compared to the template and scored.
In recent years, besides the individual application of ligand-
and structure-based VS methods, combined techniques have also
been proposed (Sperandio et al., 2008; Wilson and Lill, 2011).
Even though docking is the most widely used approach in early
phase drug discovery, a recent study has shown that ligand-based
virtual screening methods in general yield a higher fraction of
potent hits (Ripphausen et al., 2010). It is also important to note
that hits with low nanomolar potency are rarely identified by VS
(Eckert and Bajorath, 2007). However, compounds for further
chemical exploration are predominantly provided.
Ligand-based VS applies two-dimensional (e.g., 2D-
fingerprint) or three-dimensional (e.g., 3D-pharmacophore)
searches between large compound databases and already known
active molecules. This technique essentially neglects the target
structure and allows a prioritization of molecules based on the
Similar Property Principle, the assumption that compounds
with similar descriptors tend to exhibit similar biological activity
(Koeppen et al., 2011). Typically, topology-based descriptors of
the known active compounds and the potential bioactive hits
are compared to quantify molecular similarity. A major problem
related to similarity methods is their bias toward input molecules
and difficulty in making decision which structure to use as input
(Venkatraman et al., 2010).
Beside similarity searching, the ligand-based pharmacophore
method is also applied in VS. Pharmacophore models are usually
built by using a set of structurally and functionally diverse
ligands. This method is not only used to identify novel hit
compounds, but also for profiling and anti-target modeling to
avoid side-effects resulting from off-target activity (Schuster,
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2010). However, ligand-based virtual screening is often applied
in combination with structure-based approaches to identify
potential hit molecules.
In contrast to ligand-based approaches, which allow the
identification of chemically similar ligands, SBVS offers
the possibility of discovering ligands with new scaffolds or
chemical functional groups. SBVS categories, such as shape
similarity, structure-based pharmacophores and docking,
require knowledge of the three-dimensional structure of target
protein. Structures for target proteins are usually obtained by
X-ray crystallography or nuclear magnetic resonance (NMR)
spectroscopy. In cases when this information does not exist,
which is common in membrane receptors such as GPCRs,
homology models can be used instead (Cavasotto, 2011).
Structure-based pharmacophore models are developed on the
basis of the active site and can be used to screen a compound
database. Such pharmacophores are obtained by investigating
all possible interaction sites in a binding pocket (Leach et al.,
2010). Energy-based and geometry-based methods are applied to
identify potentially important interaction sites and translate them
into pharmacophore features. Typically, a binding pocket has a
higher number of potential interaction sites than are normally
observed actually being used in protein-ligand complexes.
The combination of the structure- and ligand-based VS
strategies also occurs in many CADD studies (Drwal and
Griffith, 2013). Sequential, parallel or hybrid combinations of
VS techniques take into account all available chemical and
biological information and thereby mitigate the drawbacks of
each individual method (Figure 6; Hein et al., 2010; Wilson
and Lill, 2011). Most of the recently published CADD studies
apply a sequential VS approach (Khan et al., 2010; Weidlich
et al., 2010; Drwal et al., 2011; Banoglu et al., 2012). In this
approach ligand- and structure-based strategies are used in the
VS protocol to gradually filter the large databases until the
number of remaining potential hit compounds is small enough
for biological testing. In parallel combination of VS methods,
ligand- and structure-based strategies are run independently. Top
ranked hit compounds are selected by a consensus aproach and
processed for further biological testing. Benchmarking studies
with retrospective analysis of performance have shown that
successful application of parallel methods in VS is possible (Tan
et al., 2008; Swann et al., 2011; Svensson et al., 2012). The Hybrid
VS approach integrates ligand- and structure-based methods
into one technique (protein-ligand pharmacophores) in order to
enhance the accuracy of performance (Chen et al., 2010; Postigo
et al., 2010; Spitzer et al., 2010; Drwal et al., 2011; Planesas et al.,
2011).
During the last decade, many virtual screening methods have
been developed and applied to discover novel potent ligands for
the treatment of various neurological diseases. Several successful
cases of reported virtual screening studies used to identify
promising hits for CNS drugs discovery have been listed in
Table 5. In this chapter we provide an overview of some of them
that are significant from the polypharmacological point of view.
Lepailleur and co-workers applied pharmacophore-based
virtual screening in combination with similarity based
clustering method and molecular docking to identify dual
H3R antagonist/5HT4R agonists (Lepailleur et al., 2014). Novel
ligands would have potential for treatment of neurodegenerative
diseases such as Alzheimer’s disease. A three-dimensional
pharmacophore model was constructed based on a set of six H3R
antagonists developed by different pharmaceutical companies,
using Catalyst software implemented in Discovery Studio 3.5
(Accelrys Inc., San Diego, CA, USA). This model was used as
a search query for virtual screening of the CERMN chemical
library (www.cermn.unicaen.fr) with a focus on serotonin
(5-HT) “privileged structures“. Binding experiments confirmed
that benzo[h]-[1,6]naphthyridine ligands selected by this VS
approach exert high affinity for both H3 and 5-HT4 receptors.
Recently, Bottegoni et al. carried out a virtual ligand screening
protocol to identify fragments that display considerable activity
at both β-secretase 1 (BACE-1) and glycogen synthase kinase
3β (GSK-3β) (Bottegoni et al., 2015). Discovery of multitarget
drugs which are able to modulate BACE-1 and GSK-3 β activity
simultaneously represents a promising strategy in the treatment
of Alzheimer’s disease. In this study, a VS approach based
on docking simulations and Tanimoto similarity analysis was
applied on the ZINC database (www.zinc.docking.org). Top
ranked compounds selected by VS were tested in vitro and one
with activitiy in the low-micromolar range at both enzimes
was identified as a hit. Potential acetylcholinesterase inhibitors
were also discovered using a virtual screening approach, in
combination with molecular docking (Lu et al., 2011). Three-
dimensional pharmacophore models were constructed based on
a set of known AChE inhibitors. Virtual screening performed
on the National Cancer Institute (NCI) compound database
obtained nine new inhibitors that can block both catalytic and
peripheral anionic sites of AChE. Designing or identifying
dual-acting inhibitors that block both AChE binding sites is
essential in preventing the degradation of acetylcholine in the
brain and in protection of neurons from Abeta (Aβ) toxicity.
Finally it can be concluded that most of the recent successfully
performed drug discovery studies used a sequential combination
of ligand and structure-based virtual screening techniques, with
particular focus on pharmacophore models and the docking
approach.
Docking of Multi-Target Compounds for
Neurodegenerative Diseases
Docking is a computational technique that predicts the preferred
orientation of one molecule toward the other (Lengauer and
Rarey, 1996). It is widely utilized as a hit identification and lead
optimization tool, before compound synthesis, if the structure of
the target is reliably known (Kitchen et al., 2004). In this chapter,
the focus will be on some of the most commonly used docking
software (Table 6).
Ligand-protein docking samples the conformations of small
molecules—igands—in binding sites of proteins, and scoring
functions are used to evaluate which of these conformations
best fits the protein binding site (Warren et al., 2006). Thus,
it calculates and ranks the complexes resulting from the
association between a certain ligand and a target protein of
known three-dimensional structure (Sousa et al., 2006). Initially
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FIGURE 6 | Sequential, parallel or hybrid combinations of VS techniques.
TABLE 5 | Reported virtual screening studies used in CNS drug discovery.
Compounds CNS diseases Virtual screening method Software package References
BACE1 (beta-secretase 1)
inhibitors
AD SB approach based on pharmacophore model
and molecular docking
LigandScout 1.03
www.inteligand.com GOLD
3.2 www.ccdc.cam.ac.uk
Vijayan et al., 2009
NK3 receptor antagonists Schizophrenia;
depression; anxiety
Sequential similarity analysis followed by
CoMFA
ROCS 2.4.1. and 3.0
www.eyesopen.com
Geldenhuys et al., 2010
AChE inhibitors AD LB approach based on pharmacophore model
and molecular docking
Discovery Studio 2.5.5
www.accelrys.com LibDock
(Diller and Merz, 2001)
Lu et al., 2011
Human DOPA
Decarboxylase Inhibitors
PD SB approach based on pharmacophore model
and molecular docking
MOE; Dovis 2.0; (Jiang
et al., 2008) AutoDock Vina
http://vina.scripps.edu/
Daidone et al., 2012
Histamine H3receptor
ligands
PD; AD; epilepsy;
sleeping disorders
LB and structure-based virtual fragment
screening
FLAP
www.moldiscovery.com
Sirci et al., 2012
MAO-B inhibitors PD LB virtual screening based on scaffold hopping
approach
vROCS 3.0
www.eyesopen.com
Geldenhuys et al., 2012
SERT (serotonin transporter)
Inhibitors
Depression LB virtual screening based on two- and
three-dimensional similarities; flexibile docking
JChem
www.chemaxon.com
Discovery studio
Gabrielsen et al., 2014
BuChE inhibitors AD LB virtual screening based on two- and
three-dimensional similarities
LiSiCA Lešnik et al., 2015
Serotonine 5-HT6
antagonists
AD; schizophrenia;
obesity
LB virtual approach based on two-dimensional
similarities and pharmacophore model
InstJChem;
JChemForExcel;
www.chemaxon.com
Phase-program
www.schrodinger.com
Dobi et al., 2015
H3R antagonist/5HT4R
agonist
AD LB approach based on pharmacophore model
similarity based clustering method and
molecular docking
Discovery Studio 3.5
www.accelrys.com LibMCS
http://www.chemaxon.com/
jchem/doc/user/LibMCS.
html Glide Induced-Fit
Docking http://www.
schrodinger.com/Induced-
Fit/
Lepailleur et al., 2014
BACE-1/GSK-3 β activity AD SB approach based on molecular docking
followed by Tanimoto ligand similarity
Monte Carlo stochastic
optimizer implemented in
ICM (Abagyan and Totrov,
1994)
Bottegoni et al., 2015
rigid docking was used, where both target and compound
were rigid. However, advances in both software and computer
power mean that full flexibility on the ligand can now be
allowed, and this approach is the most popular now. There are
three general kinds of algorithms formulated to apply ligand
flexibility: systematic methods, random or stochastic methods,
and simulation methods. Systematic search algorithms explore
all the degrees of freedom in a molecule, random search
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TABLE 6 | Recent docking studies employed to identify potential inhibitors for neurological targets.
Compounds CNS diseases Software package References
MAO-A inhibitors Depression AutoDock http://autodock.scripps.edu/ Evranos-Aksoz et al., 2015
Metallothionein-III inhibitors AD Discovery Studio 2.5.5 www.accelrys.com Roy et al., 2015
Sirtuin inhibitors AD GLIDE http://www.schrodinger.com/Glide Karaman and Sippl, 2015
MAO-A, MAO-B, AChE, BuChE
inhibitors
AD GLIDE http://www.schrodinger.com/Glide Bautista-Aguilera et al.,
2014b,c
AMPK2 inhibitors Stroke AutoDock, FlexX
http://autodock.scripps.edu/
https://www.biosolveit.de/FlexX/
Park et al., 2014
MAO- B inhibitors PD, AD AutoDock, GOLD, LibDock Yelekci et al., 2013
Dopamine transporter inhibitors ADHD, PD, depression and addiction MOE https://www.chemcomp.com/ Schmitt et al., 2010
algorithms explore the conformational space by applying random
changes to a single ligand or a group of ligands, and simulation
methods utilize a different approach to the docking process
such as molecular dynamics (MD) or energy minimization
methods (Sousa et al., 2006). Also, many scoring functions
have been reported over the years, and classified as force-
field-based, empirical, and knowledge-based. The first category
uses available force fields to calculate the direct interactions
between protein and ligand atoms (frequently comprising the
non-covalent energy terms covering the electrostatic energy, the
van der Waals (vdW), and hydrogen bonding). Secondly, an
empirical scoring function calculates the fitness of protein—
ligand binding by summing up the contributions of various
individual terms, each representing a significant energetic
factor in protein—ligand binding. The third type of method
utilizes pairwise statistical potentials between protein and
ligand, based on the occurrence frequencies of particular atom-
atom interaction frequencies in databases of protein-ligand
complex structures (Mitchell et al., 1999). Recently, methods that
bring pharmacophore and structure—activity relationship (SAR)
analysis into protein—ligand interaction assessment have been
introduced, representing new trends in this field (Hu and Lill,
2014).
Today, there are numerous docking software packages
available, based on different search algorithms and scoring
functions. None of the existing docking programs and scoring
functions is uniquely excellent and the improvements are
still continuing. The best way is to apply several docking
programs in order to reduce the artifacts. The three widely
used software tools are CDOCKER (Wu et al., 2003), GOLD
(Jones et al., 1995) and AutoDock (Morris et al., 1998,
2009).
The usage of docking tools in discovery of novel compounds
for neurodegenerative diseases could be explained through the
example of our study on MAO -A and B inhibitors. The
crystal structure of human MAO-A (hMAO-A) complexed
with the reversible inhibitor harmine (PDB 2Z5X) (Son et al.,
2008) and the crystal structure of human MAO-B (hMAO-B)
co-crystallized with the reversible inhibitor safinamide (PDB
2V5Z) (Binda et al., 2007) were extracted from the Protein
Data Bank (PDB) (Berman et al., 2000; http://www.rcsb.org)
for protein setup. Studies were carried out on only one
subunit of the enzymes. Each structure was cleaned of all
water molecules and inhibitors and all non-interacting ions
were removed before being used in the docking studies. For
each protein, all hydrogens were added and the protein is
minimized using the Discovery Studio protocol (accelrys.com),
assigning a CHARMM force field. Missing hydrogen atoms were
added on the basis of the protonation state of the titratable
residues at a pH of 7.4. Ionic strength was set to 0.145 and
the dielectric constant was set to 10. Molecular models of
the inhibitors were built and optimized using SPARTAN 10.0.
Docking was performed using AutoDock 4.2. For coordinates
of the binding pocket, the N5 atom of the FAD molecule was
taken, and the chosen region covers the entire binding site and its
neighboring residues. Compounds were docked in both MAO-
A and MAO-B and the selectivity was compared. To study
the binding pose of these compounds, several representative
ligands were chosen, the important interactions were visualized
in the Accelrys Visualization 4.5. program. Analysis of binding
modes revealed that aromatic groups of these compounds
in hydrophobic cage of MAO-A and MAO-B enzymes were
important for affinity (Figures 7, 8; Evranos-Aksoz et al.,
2015).
CONCLUDING REMARKS
Extensive use of computational methods such as data mining,
cheminformatics, QSAR modeling, virtual screening and
docking, provide a time and cost efficient drug discovery
processes.
These methods have become an integral part of drug
discovery. A wide range of computational tools is being
developed and used to obtain hits that are more likely to give
potential clinical candidates. However, despite their success,
both ligand- and structure-based techniques face challenges
and limitations that should be considered during application.
In recent years, integration of various cheminformatic, QSAR,
virtual screening and docking protocols has become very
popular, since it enhances their strength and applicability.
This chapter focuses on various computation methodologies
successfully applied in CNS drug discovery processes, such as
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FIGURE 7 | 3D and 2D representations of compound 5e(R) binding mode in the active site of MAO-A.
FIGURE 8 | 3D and 2D representations of compound 5e(R) binding mode in the active site of MAO-B.
design of novel donepezil–indolyl hybrids, N-Methyl-N-((1-
methyl-5-(3-(1-(2-methylbenzyl)piperidin-4-yl)propoxy)-1H-
indol-2-yl)methyl)prop-2-yn-1-amine, and donepezil-pyridyl
hybrids, as multitarget inhibitors of acetylcholine esterase and
MAO (AChE/BuChE/MAO-A/MAO-B) that were effective drug
candidates for therapy of neurodegenerative Alzheimer’s (AD)
and Parkinson’s diseases (PD).
Detailed analysis of the recently reported case studies revealed
that the majority of them use a sequential combination of ligand
and structure-based virtual screening techniques, with particular
focus on pharmacophore models and the docking approach.
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